Company intelligence / Profile preview

ChemoCentryx

Mountain View, California, United Stateschemocentryx.com ↗

Ownership: Public · CCXI
Employees: ~200
Development stage: Other

Overview

ChemoCentryx has successfully commercialized TAVNEOS (avacopan), the first approved orally administered inhibitor of the complement 5a receptor for treating severe active ANCA-associated vasculitis. The company was acquired by Amgen in October 2022 for $4 billion.

Therapeutic areas: OncologyImmunologyDermatologyNephrology
Modalities: Small moleculesOrally-administered therapies
Industry: Biotech

Partnerships

Vifor Pharma (Kidney Health Alliance)

Beyond the preview

Go deeper on ChemoCentryx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChemoCentryx.